Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are promising cancer treatments ... they efficiently targeted HR-deficient cancer cells for apoptosis through a process called synthetic ...

These cancer cells have switched to this backup system to repair DNA damage and by turning it off, PARP inhibitors cause them to die from a process known as “synthetic lethality” as mutations ...

Inhibition of PARP activity, especially in cancer cells ... This phenomenon, called “synthetic lethality,” underpins the rationale for employing PARPis in cancer therapy”.

[48–50] Final data remain to be published. Table 1. Poly-(ADP-ribose) polymerase inhibitors in clinical studies. PARP inhibitor Number of completed or ongoing studies Type of studies completed ...

Poly(ADP-ribose) polymerase (PARP) inhibitors are effective therapy for patients with mCRPC and certain homologous recombination repair gene mutations. PARP inhibitors may be given as monotherapy or ...

Her team recently developed a small nanocarrier that actively delivers a poly (ADP-ribose) polymerase (PARP) inhibitor and a demethyltransferase 1 (DNMT1) inhibitor to tumors in mouse cancer models. 1 ...

Q4 2024 Management View CEO Panna Sharma highlighted 2024 as a transformational year, emphasizing the company's advancements in computational and AI-driven drug discovery, particularly in precision ...